In his masterpiece War and Peace (1869), Leo Tolstoy wrote: “The human intellect with no inkling of the immense variety and complexity of circumstances conditioning a phenomenon, any one of which may be separately conceived as the cause of it, snatches at the first and the most easily understood approximation, and says: ‘Oh, here is the cause!’” The field of type 1 diabetes has been plagued by this trend for oversimplification. As a result, individual pathways are often suggested as “the cause” of this complex, multifactorial, and probably heterogeneous disease, thereby leading to therapeutic attempts that nearly always end in failure.
MicroRNAs (miRNAs) are a family of endogenous single-stranded RNA molecules around 22 nucleotides in length (1). They are highly conserved among species and regulate the expression of partially complementary protein-coding genes by either degrading or preventing translation of target messenger RNAs. miRNAs are transcribed from individual genes, located in exons or introns of protein-coding genes or in intergenic regions, and are often clustered (2). Importantly, >50% of human genes may be at least in part regulated by miRNAs (3), adding an extra level of regulation for gene expression. An article by Roggli et al. (4) published in this issue of Diabetes describes a microarray analysis on islets obtained from 4- and 8-week-old female NOD mice (an animal model of autoimmune diabetes, in which 4-week-old animals have little or no immune infiltration whereas 8-week-old mice show insulitis in most islets; hyperglycemia usually starts after 14 weeks of age). They observed a preferential increase in miR-29a/b/c in the islets obtained from 8-week-old animals, a finding confirmed by other methods in islets from 13- to 14-week-old NOD mice and in isolated human and mouse islets exposed to the proinflammatory cytokines interleukin-1β, tumor necrosis factor-α, and interferon-γ, cytokines that probably contribute to β-cell apoptosis in type 1 diabetes (5). Quantitative PCR and in situ hybridization analysis, coupled with immunofluorescence for insulin, confirmed that increased miR-29 expression takes place in β-cells and not in the infiltrating immune cells. In subsequent and elegant mechanistic studies, they showed that overexpression of miR-29a/b/c in insulin-producing MIN6 cells and dissociated mouse islets contributes to impaired glucose-induced insulin release and apoptosis by respectively inhibiting expression of the transcription factor Onecut2 (which leads to a rise in granuphilin, an antagonist of insulin exocytosis [6,7]) and of the antiapoptotic Bcl-2 family member Mcl-1, which plays an important protective role against cytokine-induced β-cell apoptosis (8). These findings, together with previous observations from the same group (confirmed in the current study) showing that prolonged exposure of pancreatic β-cells to proinflammatory cytokines induces expression of three other miRNAs (miR-21, miR-34a, and miR-146, which also affect insulin release and apoptosis) (9), strongly suggest that preferential induction of key miRNAs during islet inflammation constitutes a novel level of regulation of β-cell dysfunction and apoptosis during the early stages of type 1 diabetes.
This publication, together with other recent articles suggesting that proinflammatory cytokines modify alternative splicing (AS) in human islets (10,11) and that >60% of the candidate genes for type 1 diabetes may actually act at the pancreatic islet level (11–13), support two conclusions: First, an important part of the action in type 1 diabetes takes place at the pancreatic β-cell level, changing the purely “immune system–centric” vision that has prevailed up to now in the field; and second, the “decision” of the pancreatic β-cell to undergo apoptosis, a central event in type 1 diabetes, depends on several layers of regulation. This regulation includes gene transcription, AS, expression of noncoding messenger RNAs (such as miRNAs and probably also large noncoding RNAs) and posttranslational modifications of proteins secondary to endoplasmic reticulum stress and other mechanisms. As described in Fig. 1, these “checks and balances” may impact β-cell death, expression of neoantigens, and attraction of immune cells.
Although the current and previous studies in the miRNA field (17,18) have yielded a new group of regulatory factors in the natural history of β-cell loss in diabetes, many questions remain to be answered. Do candidate genes for type 1 diabetes impact miRNA expression, as they seem to do for other β-cell gene regulators and effector mechanisms? Which are the transcription factors that regulate expression of the miR-29 family? Is there a cross-talk between key cytokine-modulated transcription factors and miRNAs in the regulation of effector mechanisms of β-cell dysfunction and death? Given that miRNAs also regulate cells from the immune system in type 1 diabetes (17,18), is there similarity or cross-talk between these miRNAs and the ones implicated in β-cell dysfunction/death? Because AS can regulate the effect of miRNAs by removing/adding potential binding sites for these molecules, is there a cross-talk between cytokine-induced AS and miRNAs in pancreatic β-cells? Since MiRNAs are surprisingly stable in circulation and have been suggested as biomarkers for cancer (19), can they be used as early biomarkers for β-cell dysfunction/death and/or activation of the immune system against these cells?
Thanks to recent advances in technology that allow reliable determination of all coding and noncoding transcripts in pancreatic β-cells and other cell types, as well as the development of novel bioinformatics tools that enable organization and interpretation of these “data mountains,” we are for the first time able to face the immense variety and complexity of circumstances conditioning progressive β-cell loss in type 1 diabetes. Integration of these findings with ongoing work focused on understanding the loss of immune tolerance against β-cells in early type 1 diabetes (20) will hopefully point to novel and rational targets to prevent/revert the disease.
Research in the laboratory of D.L.E. is supported by grants from the European Union (projects BetaBat and Naimit in the Framework Programme 7 of the European Community), JDRF, the Fonds National de la Recherche Scientifique: Belgium, and the Communauté Française de Belgique–Actions de Recherche Concertées (ARC).
No potential conflicts of interest relevant to this article were reported.
See accompanying original article, p. 1742 .
- © 2012 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.